Protalix up as genetic disorder therapy inches closer to EC's approval

PLx Pharma Winddown

24/02/2023 17:21

** U.S.-listed shares of Israeli drug developer Protalix
Biotherapeutics Inc  PLX.N  rise 12.9% to $1.93 
    ** PLX and partner Chiesi Global Rare Diseases said European
Medicines Agency's (EMA) expert panel advised for approval of
PLX's jointly developed enzyme replacement therapy, PRX–102, as
a potential treatment of Fabry disease
    ** Fabry disease is a rare genetic disorder that causes a
range of symptoms, including a progressive impairment of kidneys
leading to renal failure
    ** Final decision by European Commission (EC) on co's
marketing application for PRX-102 is expected in the beginning
of May 2023 
    ** PLX's U.S.-listed stock gained 65.8% in 2022
 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))